On February 2, 2025, Shanghai Henlius Biotech, Inc. (“Henlius”) announced FDA acceptance of the Biologics License Application (BLA) for HLX11, a proposed biosimilar to Genentech’s PERJETA.

Department of Pharmaceutical Chemistry, Drug Analyses and Radiopharmacy, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Lodz, Poland ...

Pharmac is reconsidering its decision to fund only one brand of HRT oestrogen patches after receiving considerable feedback. The patches are used by menopausal people as a hormone replacement therapy ...

blockade with trastuzumab and pertuzumab with the current standard of care, taxane plus trastuzumab and pertuzumab, in HER2-positive metastatic breast cancer (MBC). Compared with the taxane-based ...

LBA331: The EORTC-1203 GITC INNOVATION trial (NCT02205047) is evaluating the integration of trastuzumab (Herceptin), with or without pertuzumab (Perjeta), into perioperative chemotherapy for patients ...

Associate Health Minister David Seymour has commended Pharmac’s progress in expanding access to essential medicines for New Zealanders, driven by the government’s historic $6.294 billion funding ...

Objective: The aim of this paper was to assess the differences in clinicopathological characteristics, efficacy and prognosis of neoadjuvant chemotherapy (NAC) in human epidermal growth factor ...

We are working with Guy’s and St. Thomas’ NHS Foundation Trust to produce national standardised SACT regimen-specific consent forms. We want to support clinicians in ensuring all patients are fully ...

Every item on this page was chosen by an ELLE editor. We may earn commission on some of the items you choose to buy. True beauty obsessives know that a trip to Paris isn’t complete without a ...

The first therapy given is usually chemotherapy in combination with trastuzumab (Herceptin, other names) and pertuzumab (Perjeta), both HER2 targeted drugs. If the cancer grows, other options might ...

Compared to the combination of trastuzumab and pertuzumab, the VHH-Fc combos or their combination with trastuzumab demonstrated greater or comparable antitumor activity in both ligand-independent and ...

or pertuzumab. People who might be treated with this regimen must also not have mutations in the RAS and BRAF genes. Among these drugs, only tucatinib is FDA approved specifically to treat colorectal ...